6082613 [online] Available at: Maeda-Yamamoto, M., Nishimura, M., Kitaichi, N., Nesumi, A., Monobe, M., Nomura, S., Horie, Y., Tachibana, H
To further explore the relationship between gene expression and anthocyanin content, with ripe fruit of all 12 cultivars, correlation analysis was carried out between anthocyanin content and transcript levels of MrGST1 , as well as anthocyanin biosynthetic genes and transcription factors (Figure 3)
References Journal of Endocrinology & Metabolism (2014) Safety and metabolism of AOD9604: novel nutraceutical ingredient for improved metabolic health Journal of Clinical Endocrinology & Metabolism (PubMed) Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults European Journal of Endocrinology (PubMed) Ipamorelin: the first selective growth hormone secretagogue Translational Andrology and Urology (PMC) Role of growth hormone secretagogues in body composition management Endocrinology (OUP) hGH and AOD-9604: lipid metabolism and beta-adrenergic pathway insights CDC Preventing unsafe injection practices: multi-dose vial handling guidelines Journal of Endocrinology & Metabolism (2013) Safety and tolerability of the hexadecapeptide AOD9604 in humans Obesity Pharmacotherapy Review (PMC) AOD-9604 clinical trial overview and weight loss outcomes Subcutaneous Drug Injection Review (PMC) Pharmacologic considerations of the subcutaneous route CDC Vaccine administration: subcutaneous route (angle/site guidance) MedlinePlus Subcutaneous injections: patient instructions and technique NCBI Bookshelf Best practices for injection: asepsis, preparation, and administration Additional Research and Background These sources provide related context and are not presented as support for a specific statement above
Mild temporary symptoms may include: Redness at injection site Light nausea Slight fatigue or headache during adjustment phase Not recommended for individuals with active cancers or certain metabolic conditions our physicians will evaluate your history during consultation
The formal FDA publication updating the Category 1 list had not been released as of April 6, 2026
